StockData
Repligen Corp logo

Repligen Corp (RGEN) bonds

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)

Close on Nov 18, 2026Market cap $11.04BP/E –Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Repligen reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Repligen's 10-Q for the period ended Sep 30, 2026

IssueCouponMaturesAmount issuedCarrying value
1.00% Convertible Senior Notes due 2028
Convertible at $203 a share
1.00%Dec 15, 2028$600.00M$555.60M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?